Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2014 1
2015 17
2016 19
2017 20
2018 10
2019 16
2020 11
2021 14
2022 12
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Cobimetinib.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999907 Free Books & Documents. Review.
No information is available on the clinical use of cobimetinib during breastfeeding. Because cobimetinib is 90% bound to plasma proteins, the amount in milk is likely to be low. ...The manufacturer recommends that breastfeeding be discontinued during cobimetinib …
No information is available on the clinical use of cobimetinib during breastfeeding. Because cobimetinib is 90% bound to plasm …
Cobimetinib.
Signorelli J, Shah Gandhi A. Signorelli J, et al. Ann Pharmacother. 2017 Feb;51(2):146-153. doi: 10.1177/1060028016672037. Epub 2016 Oct 4. Ann Pharmacother. 2017. PMID: 27701080 Review.
STUDY SELECTION AND DATA EXTRACTION: The literature search was confined to human studies published in English. Trials of cobimetinib for melanoma were prioritized. DATA SYNTHESIS: Cobimetinib is a reversible inhibitor of MEK1 and MEK2. ...The role of cobimetinib …
STUDY SELECTION AND DATA EXTRACTION: The literature search was confined to human studies published in English. Trials of cobimetinib …
Cobimetinib.
[No authors listed] [No authors listed] 2017 Jun 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jun 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643968 Free Books & Documents. Review.
Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of advanced malignant melanoma. The combination of cobimetinib and vemurafenib is commonly associated with serum enzyme elevations during t …
Cobimetinib is a tyrosine kinase receptor inhibitor that is used in combination with vemurafenib as therapy for selected forms of adv …
Cobimetinib (GDC-0973, XL518).
Andrlová H, Zeiser R, Meiss F. Andrlová H, et al. Recent Results Cancer Res. 2018;211:177-186. doi: 10.1007/978-3-319-91442-8_12. Recent Results Cancer Res. 2018. PMID: 30069767 Review.
Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past. After trametinib, cobimetinib is another potent, selective oral MEK1/2 inhibitor that was approved by European Medicine Agency (EMA) and Food and Drug Administration (FDA) in 2015 …
Several MEK inhibitors have been studied for metastatic cancer treatment in the recent past. After trametinib, cobimetinib is another …
Cobimetinib and vemurafenib for the treatment of melanoma.
Boespflug A, Thomas L. Boespflug A, et al. Expert Opin Pharmacother. 2016;17(7):1005-11. doi: 10.1517/14656566.2016.1168806. Expert Opin Pharmacother. 2016. PMID: 26999478 Review.
INTRODUCTION: Cobimetinib combined with vemurafenib is a new approved MEK inhibitor for first line treatment of metastatic melanoma patients with BRAF V600 mutations. ...AREAS COVERED: This review covers the pharmacology, efficacy, and toxicity data derived from clinical a …
INTRODUCTION: Cobimetinib combined with vemurafenib is a new approved MEK inhibitor for first line treatment of metastatic melanoma p …
Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Indini A, Tondini CA, Mandalà M. Indini A, et al. Future Oncol. 2019 Mar;15(9):967-977. doi: 10.2217/fon-2018-0659. Epub 2019 Jan 14. Future Oncol. 2019. PMID: 30638071 Review.
The toxicity profile of cobimetinib is manageable and treatment discontinuation due to adverse events is uncommon. Present efforts are addressed to overcome resistance and improve long-term outcomes: based on the evidence of the immunomodulatory properties of BRAFi and MEK …
The toxicity profile of cobimetinib is manageable and treatment discontinuation due to adverse events is uncommon. Present efforts ar …
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM, Dumas L, Larkin J. Schmitt AM, et al. Expert Rev Anticancer Ther. 2022 Jan;22(1):17-25. doi: 10.1080/14737140.2022.2017286. Epub 2022 Jan 2. Expert Rev Anticancer Ther. 2022. PMID: 34904502 Review.
The IMspire150 trial investigated the combination of atezolizumab, cobimetinib and vemurafenib versus cobimetinib and vemurafenib alone. ...The combination is compared with the current standard of care including BRAF/MEK inhibition and treatment with immune checkpoi …
The IMspire150 trial investigated the combination of atezolizumab, cobimetinib and vemurafenib versus cobimetinib and vemurafe …
Cobimetinib: First Global Approval.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2015 Oct;75(15):1823-30. doi: 10.1007/s40265-015-0477-8. Drugs. 2015. PMID: 26452567 Review.
Genentech (a subsidiary of Roche) and Exelixis are developing cobimetinib, an orally available small molecule, for the treatment of various cancers, including malignant melanoma and breast cancer. Cobimetinib inhibits the MEK (mitogen-activated protein kinase) compo …
Genentech (a subsidiary of Roche) and Exelixis are developing cobimetinib, an orally available small molecule, for the treatment of v …
Cobimetinib for metastatic melanoma.
[No authors listed] [No authors listed] Aust Prescr. 2017 Feb;40(1):30-31. doi: 10.18773/austprescr.2016.095. Epub 2017 Feb 1. Aust Prescr. 2017. PMID: 28246434 Free PMC article. Review. No abstract available.
Melanoma.
Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Schadendorf D, et al. Nat Rev Dis Primers. 2015 Apr 23;1:15003. doi: 10.1038/nrdp.2015.3. Nat Rev Dis Primers. 2015. PMID: 27188223 Review.
Alongside other new drugs - namely, BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib and cobimetinib) - these agents are very promising and have been shown to significantly improve prognosis for patients with advanced-stage metastatic disease. .. …
Alongside other new drugs - namely, BRAF inhibitors (vemurafenib and dabrafenib) and MEK inhibitors (trametinib and cobimetinib) - th …
111 results